# Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

> **NCT05743504** · PHASE1,PHASE2 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Locally Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tiragolumab

## Key facts

- **NCT ID:** NCT05743504
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-18
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-11-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2024-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05743504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05743504, "Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05743504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*